Health Canada Recalls Three Organika Gummy Lots Over Unlisted Manufacturing Site

Health Canada published a Type III recall on September 15, 2026, covering three Organika gummy supplement lots because a foreign manufacturing site was not listed on the company’s site licence. The notice is primarily relevant to community pharmacists and other retailers that stock natural health products.

The federal notice identifies the regulatory issue as a foreign site not listed on the site licence. It does not extend the recall to every Organika product or to lots other than those listed above.

Practice guidance for pharmacists

• Check on-hand inventory against the exact product name, NPN and lot number in the Health Canada notice.
• Quarantine affected units immediately and prevent sale or dispensing while following wholesaler or manufacturer return instructions.
• Document quantities removed, return actions and any patient contacts according to the pharmacy’s recall procedure.
• Explain to patients that the notice is lot-specific; avoid advising them that all Organika gummies are recalled.
• Direct suspected adverse reactions to Health Canada’s Canada Vigilance reporting process and retain the product details needed for a report.

Because the affected items are natural health products rather than prescription medicines, they may sit outside some dispensary inventory workflows. Pharmacy teams should include front-shop supplement stock when completing the recall check.